Skip to main content Accessibility help

The Ontario Neurodegenerative Disease Research Initiative (ONDRI)

  • Sali M. K. Farhan (a1) (a2), Robert Bartha (a2) (a3), Sandra E. Black (a4) (a5), Dale Corbett (a6), Elizabeth Finger (a7), Morris Freedman (a8) (a9), Barry Greenberg (a10), David A. Grimes (a11), Robert A. Hegele (a1) (a2), Chris Hudson (a12), Peter W. Kleinstiver (a13), Anthony E. Lang (a14), Mario Masellis (a4), William E. McIlroy (a15), Paula M. McLaughlin (a13), Manuel Montero-Odasso (a16), David G. Munoz (a17), Douglas P. Munoz (a18), Stephen Strother (a19), Richard H. Swartz (a20), Sean Symons (a21), Maria Carmela Tartaglia (a22), Lorne Zinman (a4), ONDRI Investigators and Michael J. Strong (a2) (a7)...


Because individuals develop dementia as a manifestation of neurodegenerative or neurovascular disorder, there is a need to develop reliable approaches to their identification. We are undertaking an observational study (Ontario Neurodegenerative Disease Research Initiative [ONDRI]) that includes genomics, neuroimaging, and assessments of cognition as well as language, speech, gait, retinal imaging, and eye tracking. Disorders studied include Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and vascular cognitive impairment. Data from ONDRI will be collected into the Brain-CODE database to facilitate correlative analysis. ONDRI will provide a repertoire of endophenotyped individuals that will be a unique, publicly available resource.

L’initiative de recherche sur les maladies neurodégénératives en Ontario. La démence constituant la manifestation d’un trouble neurodégénératif ou neurovasculaire, il importe de mettre au point des approches fiables permettant son identification. Nous somme ainsi en train de mener une étude observationnelle – Initiative de recherche sur les maladies neurodégénératives en Ontario ou « ONDRI » – qui inclut l’analyse du génome, la neuro-imagerie et diverses techniques d’évaluation en lien avec les aspects suivants : la cognition, le langage, la démarche, l’imagerie rétinienne et le suivi du regard. Parmi les affections à l’étude, on peut mentionner la maladie d’Alzheimer, la sclérose latérale amyotrophique, la démence fronto-temporale, la maladie de Parkinson et la déficience cognitive vasculaire. Les données de l’ONDRI seront recueillies à partir de la base de données du Brain-CODE afin de faciliter les analyses de corrélation. De plus, l’ONDRI entend fournir un répertoire des endophénotypes associés aux sujets de recherche, répertoire unique en son genre qui sera accessible au public.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The Ontario Neurodegenerative Disease Research Initiative (ONDRI)
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The Ontario Neurodegenerative Disease Research Initiative (ONDRI)
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The Ontario Neurodegenerative Disease Research Initiative (ONDRI)
      Available formats


This is an open access article, distributed under the terms of the creative commons attribution licence (, which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Correspondence to: Michael J. Strong, Room C7-120, University Hospital – LHSC, 339 Windermere Road, London, Ontario, N6A 5A5. Email:


Hide All
1. World Alzheimer Report 2013. Journary of caring. An analysis of long-term care of dementia. Available from: (accessed August 10, 2016).
2. WHO takes up the baton on dementia. Lancet Neurol. 2015;14:455.
3. Herrmann, N, Harimoto, T, Balshaw, R, Lanctot, KL. Risk factors for progression of Alzheimer Disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID). Can J Psychiatry. 2015;60:189-199.
4. Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280-292.
5. Gomersall, T, Astell, A, Nygard, L, Sixsmith, A, Mihailidis, A, Hwang, A. Living with ambiguity: a metasynthesis of qualitative research on mild cognitive impairment. Gerontologist. 2015;55:892-912.
6. Strong, MJ, Grace, GM, Freedman, M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131-146.
7. Woolley, SC, Strong, MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:787-805.
8. Dorsey, ER, Constantinescu, R, Thompson, JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384-386.
9. Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20:1255-1263.
10. Hely, MA, Reid, WG, Adena, MA, Halliday, GM, Morris, JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.
11. Kertesz, A. Frontotemporal dementia/Pick’s disease. Arch Neurol. 2004;61:969-971.
12. Saposnik, G, Cote, R, Rochon, PA, et al. Care and outcomes in patients with ischemic stroke with and without preexisting dementia. Neurology. 2011;77:1664-1673.
13. Saposnik, G, Black, SE, Hakim, A, Fang, J, Tu, JV, Kapral, MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40:3328-3335.
14. Pendlebury, ST, Mariz, J, Bull, L, Mehta, Z, Rothwell, PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43:464-469.
15. Hachinski, V, Iadecola, C, Petersen, RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
16. Montero-Odasso, M, Casas, A, Hansen, KT, et al. Quantitative gait analysis under dual-task in older people with mild cognitive impairment: a reliability study. J Neuroeng Rehabil. 2009;6:35.
17. Montero-Odasso, M, Muir, SW, Speechley, M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil. 2012;93:293-299.
18. Ghani, M, Lang, AE, Zinman, L, et al. Mutation analysis of patients with neurodegenerative disorders using NeuroX array. Neurobiol Aging. 2015;36(545):e549-514.
19. Ballard, CG, Morris, CM, Rao, H, et al. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 2004;63:1399-1402.
20. Tsuang, D, Leverenz, JB, Lopez, OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70:223-228.
21. Xi, Z, Zinman, L, Grinberg, Y, et al. Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol. 2012;69:1583-1590.
22. Friedman, L, Stern, H, Brown, GG, Mathalon, DH, Turner, J, Glover, GH, et al. Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp. 2008;29:958-972.
23. Nestor, SM, Gibson, E, Gao, FQ, Kiss, A, Black, SE. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer’s disease. Neuroimage. 2013;66:50-70.
24. Nestor, SM, Rupsingh, R, Borrie, M, et al. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain. 2008;131:2443-2454.
25. Dade, LA, Gao, FQ, Kovacevic, N, et al. Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images. Neuroimage. 2004;22:1492-1502.
26. Ramirez, J, Gibson, E, Quddus, A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage. 2011;54:963-973.
27. Wahlund, LO, Julin, P, Lindqvist, J, Scheltens, P. Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res. 1999;90:193-199.
28. Scheltens, P, Leys, D, Barkhof, F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967-972.
29. Fazekas, F, Chawluk, JB, Alavi, A, Hurtig, HI, Zimmerman, RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
30. Scheltens, P, Barkhof, F, Leys, D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7-12.
31. Cordonnier, C, Potter, GM, Jackson, CA, et al. improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke. 2009;40:94-99.
32. Holmes, C, Boche, D, Wilkinson, D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
33. Iadecola, C, Anrather, J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011;14:1363-1368.
34. Lang, AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med. 2010;16:1223-1226.
35. Farhan, SM, Dilliott, AA, Ghani, M, et al. The ONDRISeq panel: custom designed next generation sequencing of genes related to neurodegeneration. Genom Med. 2016; Article number 16032;doi:10.1038/npjgenmed.2016.32.


Type Description Title
Supplementary materials

Farhan supplementary material
Farhan supplementary material 1

 Word (21 KB)
21 KB
Supplementary materials

Farhan supplementary material
Farhan supplementary material 2

 Word (16 KB)
16 KB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed